Rauch Bernhard, Senges Jochen
Zentrum für Ambulante Rehabilitation am Klinikum der Stadt Ludwigshafen Ludwigshafen am Rhein, Germany.
Front Physiol. 2012 Apr 2;3:57. doi: 10.3389/fphys.2012.00057. eCollection 2012.
Supplementation of omega-3 fatty acids (Ω-3) has been associated with a decreased cardiovascular risk, thereby concentrating attention on a potentially preventive effect regarding tachyarrhythmias and sudden cardiac death. However, recent randomized controlled trials challenge the efficacy of the additional application of Ω-3 and its anti-arrhythmic effect under certain clinical conditions. The present paper reflects the results of earlier and recent clinical studies with respect to the individual background conditions that may determine the clinical outcome of Ω-3 supplementation and thereby explain apparently conflicting clinical results. It is concluded that the efficacy of Ω-3 supplementation to prevent cardiac arrhythmias strongly depends on the underlying clinical and pharmacological conditions, a hypothesis that also is supported by data from experimental animal studies and by molecular interactions of Ω-3 at the cellular level.
补充ω-3脂肪酸(Ω-3)与心血管风险降低有关,因此人们将注意力集中在其对快速性心律失常和心源性猝死可能的预防作用上。然而,最近的随机对照试验对在某些临床情况下额外应用Ω-3的疗效及其抗心律失常作用提出了质疑。本文反映了早期和近期临床研究的结果,涉及可能决定补充Ω-3临床结果的个体背景条件,从而解释了明显相互矛盾的临床结果。得出的结论是,补充Ω-3预防心律失常的疗效很大程度上取决于潜在的临床和药理学条件,这一假设也得到了实验动物研究数据以及Ω-3在细胞水平上的分子相互作用的支持。